CASI Pharmaceuticals, Inc.
CASI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,537 | $33,879 | $43,107 | $30,168 |
| % Growth | -15.8% | -21.4% | 42.9% | – |
| Cost of Goods Sold | $17,391 | $13,827 | $15,827 | $12,557 |
| Gross Profit | $11,146 | $20,052 | $27,280 | $17,611 |
| % Margin | 39.1% | 59.2% | 63.3% | 58.4% |
| R&D Expenses | $8,917 | $9,861 | $15,996 | $14,422 |
| G&A Expenses | $23,577 | $25,387 | $23,449 | $23,701 |
| SG&A Expenses | $41,443 | $41,837 | $37,775 | $38,406 |
| Sales & Mktg Exp. | $17,866 | $16,450 | $14,326 | $14,705 |
| Other Operating Expenses | $407 | -$6,566 | $0 | $6,299 |
| Operating Expenses | $50,767 | $45,132 | $53,771 | $59,127 |
| Operating Income | -$39,621 | -$25,080 | -$26,491 | -$41,516 |
| % Margin | -138.8% | -74% | -61.5% | -137.6% |
| Other Income/Exp. Net | $1,552 | -$1,212 | -$11,786 | $5,674 |
| Pre-Tax Income | -$38,069 | -$26,292 | -$38,277 | -$35,842 |
| Tax Expense | $1,189 | -$81 | $1,980 | $0 |
| Net Income | -$39,258 | -$26,938 | -$41,014 | -$36,654 |
| % Margin | -137.6% | -79.5% | -95.1% | -121.5% |
| EPS | -2.56 | -2.02 | -3.01 | -2.69 |
| % Growth | -26.7% | 32.9% | -11.9% | – |
| EPS Diluted | -2.56 | -2.02 | -3.01 | -2.69 |
| Weighted Avg Shares Out | 15,340 | 13,360 | 13,647 | 13,611 |
| Weighted Avg Shares Out Dil | 15,340 | 13,360 | 13,647 | 13,611 |
| Supplemental Information | – | – | – | – |
| Interest Income | $539 | $614 | $189 | $321 |
| Interest Expense | $871 | $0 | $62 | $0 |
| Depreciation & Amortization | $2,331 | $3,741 | $2,422 | $1,815 |
| EBITDA | -$34,867 | -$21,539 | -$24,069 | -$33,402 |
| % Margin | -122.2% | -63.6% | -55.8% | -110.7% |